Detail publikačního výsledku

Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs

SZABOVÁ, J.; MIŠÍK, O.; FUČÍK, J.; MRÁZOVÁ, K.; MRAVCOVÁ, L.; ELCNER, J.; LÍZAL, F.; KRZYZANEK, V.; MRAVEC, F.

Originální název

Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs

Anglický název

Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs

Druh

Článek WoS

Originální abstrakt

This contribution is focused on the preparation of a liposomal drug delivery system of erlotinib resisting the nebulization process that could be used for local treatment of non-small-cell lung cancer. Liposomes with different compositions were formulated to reveal their influence on the encapsulation efficiency of erlotinib. An encapsulation efficiency higher than 98 % was achieved for all vesicles containing phosphatidic acid (d ≈ 100 nm , ζ = – 43 mV) even in the presence of polyethylene glycol (d ≈ 150 nm, ζ = – 17 mV) which decreased this value in all other formulas. The three most promising formulations were nebulized by two air-jet and two vibrating mesh nebulizers, and the aerosol deposition in lungs was calculated by tools of computational fluid and particle mechanics. According to the numerical simulations and measurements of liposomal stability, air-jet nebulizers generated larger portion of the aerosol able to penetrate deeper into the lungs, but the delivery is likely to be more efficient when the formulation is administered by Aerogen Solo vibrating mesh nebulizer because of a higher portion of intact vesicles after the nebulization. The leakage of encapsulated drug from liposomes nebulized by this nebulizer was lower than 2 % for all chosen vesicles.

Anglický abstrakt

This contribution is focused on the preparation of a liposomal drug delivery system of erlotinib resisting the nebulization process that could be used for local treatment of non-small-cell lung cancer. Liposomes with different compositions were formulated to reveal their influence on the encapsulation efficiency of erlotinib. An encapsulation efficiency higher than 98 % was achieved for all vesicles containing phosphatidic acid (d ≈ 100 nm , ζ = – 43 mV) even in the presence of polyethylene glycol (d ≈ 150 nm, ζ = – 17 mV) which decreased this value in all other formulas. The three most promising formulations were nebulized by two air-jet and two vibrating mesh nebulizers, and the aerosol deposition in lungs was calculated by tools of computational fluid and particle mechanics. According to the numerical simulations and measurements of liposomal stability, air-jet nebulizers generated larger portion of the aerosol able to penetrate deeper into the lungs, but the delivery is likely to be more efficient when the formulation is administered by Aerogen Solo vibrating mesh nebulizer because of a higher portion of intact vesicles after the nebulization. The leakage of encapsulated drug from liposomes nebulized by this nebulizer was lower than 2 % for all chosen vesicles.

Klíčová slova

Liposome, Non-small-cell lung cancer, Nebulization, Encapsulation, Aerodynamic particle size, Numerical simulations.

Klíčová slova v angličtině

Liposome, Non-small-cell lung cancer, Nebulization, Encapsulation, Aerodynamic particle size, Numerical simulations.

Autoři

SZABOVÁ, J.; MIŠÍK, O.; FUČÍK, J.; MRÁZOVÁ, K.; MRAVCOVÁ, L.; ELCNER, J.; LÍZAL, F.; KRZYZANEK, V.; MRAVEC, F.

Rok RIV

2024

Vydáno

07.02.2023

Nakladatel

Elsevier Science BV

Místo

Holandsko

ISSN

0378-5173

Periodikum

International Journal of Pharmaceutics

Svazek

634

Číslo

march

Stát

Nizozemsko

Strany od

1

Strany do

12

Strany počet

12

URL

BibTex

@article{BUT182463,
  author="Jana {Szabová} and Ondrej {Mišík} and Jan {Fučík} and Kateřina {Mrázová} and Ludmila {Mravcová} and Jakub {Elcner} and František {Lízal} and Vladislav {Krzyžánek} and Filip {Mravec}",
  title="Liposomal Form of Erlotinib for Local Inhalation Administration and Efficiency of Its Transport to the Lungs",
  journal="International Journal of Pharmaceutics",
  year="2023",
  volume="634",
  number="march",
  pages="1--12",
  doi="10.1016/j.ijpharm.2023.122695",
  issn="0378-5173",
  url="https://www.sciencedirect.com/science/article/pii/S0378517323001151"
}